APA Alıntı

Shields, B. M., Angwin, C. D., Shepherd, M. H., Britten, N., Jones, A. G., Sattar, N., . . . Hattersley, A. T. (2023). Patient preference for second and third line therapies in type 2 diabetes: A prespecified secondary endpoint of the TriMaster study. Nat Med.

Chicago Stili Alıntı

Shields, Beverley M., Catherine D. Angwin, Maggie H. Shepherd, Nicky Britten, Angus G. Jones, Naveed Sattar, Rury Holman, Ewan R. Pearson, ve Andrew T. Hattersley. "Patient Preference for Second and Third Line Therapies in Type 2 Diabetes: A Prespecified Secondary Endpoint of the TriMaster Study." Nat Med 2023.

MLA Alıntı

Shields, Beverley M., et al. "Patient Preference for Second and Third Line Therapies in Type 2 Diabetes: A Prespecified Secondary Endpoint of the TriMaster Study." Nat Med 2023.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..